Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation, drug safety, and prescription drug abuse.
Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee and represents Pew as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
On Dec. 28, 2016, the U.S. Food and Drug Administration (FDA) finalized a guidance document interpreting provisions of federal law that govern compounded medications—customized drugs made by pharmacists or physicians rather than pharmaceutical manufacturers. “Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act” clarifies the law’s... Read More
Outsourcing facilities produce stock supplies of compounded drugs under quality standards appropriate for large-scale production. They were authorized by federal law in 2013, but the viability of this new sector depends on outsourcing facilities understanding the market for supplies of compounded drugs used by doctor’s offices and hospitals. The American Society of Health-System Pharmacists... Read More
National drug shortages, defined by the U.S. Food and Drug Administration (FDA) as a period of time when the demand or projected demand for a drug within the United States exceeds the supply of the drug, remain a complex and multilayered issue in the U.S. health care delivery system. Read More